Your browser doesn't support javascript.
loading
Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season.
Shinjoh, Masayoshi; Sugaya, Norio; Yamaguchi, Yoshio; Ookawara, Ichiro; Nakata, Yuji; Narabayashi, Atsushi; Furuichi, Munehiro; Yoshida, Naoko; Kamei, Akinobu; Kuramochi, Yuu; Shibata, Akimichi; Shimoyamada, Motoko; Nakazaki, Hisataka; Maejima, Naohiko; Yuasa, Erika; Araki, Eriko; Maeda, Naonori; Ohnishi, Takuma; Nishida, Mitsuhiro; Taguchi, Nobuhiko; Yoshida, Makoto; Tsunematsu, Kenichiro; Shibata, Meiwa; Hirano, Yasuhiro; Sekiguchi, Shinichiro; Kawakami, Chiharu; Mitamura, Keiko; Takahashi, Takao.
Afiliação
  • Shinjoh M; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Sugaya N; Department of Pediatrics, Keiyu Hospital, Kanagawa, Japan.
  • Yamaguchi Y; Institute of Clinical Research & Department of Infection and Allergy, National Hospital Organization Tochigi Hospital, Tochigi, Japan.
  • Ookawara I; Department of Pediatrics, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
  • Nakata Y; Department of Pediatrics, Nippon Koukan Hospital, Kanagawa, Japan.
  • Narabayashi A; Department of Pediatrics, Kawasaki Municipal Hospital, Kanagawa, Japan.
  • Furuichi M; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Yoshida N; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Kamei A; Department Pediatrics, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan.
  • Kuramochi Y; Department of Pediatrics, Subaru Health Insurance Society Ota Memorial Hospital, Gunma, Japan.
  • Shibata A; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
  • Shimoyamada M; Department of Pediatrics, Saitama City Hospital, Saitama, Japan.
  • Nakazaki H; Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan.
  • Maejima N; Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
  • Yuasa E; Department of Pediatrics, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
  • Araki E; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
  • Maeda N; Department of Pediatrics, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Ohnishi T; Department of Pediatrics, National Hospital Organization Saitama Hospital, Saitama, Japan.
  • Nishida M; Department of Pediatrics, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
  • Taguchi N; Department of Pediatrics, Keiyu Hospital, Kanagawa, Japan.
  • Yoshida M; Department of Pediatrics, Sano Kosei General Hospital, Tochigi, Japan.
  • Tsunematsu K; Department of Pediatrics, Hino Municipal Hospital, Tokyo, Japan.
  • Shibata M; Department of Pediatrics, Yokohama Rosai Hospital, Kanagawa, Japan.
  • Hirano Y; Department of Pediatrics, Hiratsuka City Hospital, Kanagawa, Japan.
  • Sekiguchi S; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
  • Kawakami C; Yokohama City Institute of Public Health, Yokohama, Japan.
  • Mitamura K; Department of Pediatrics, Eiju General Hospital, Tokyo, Japan.
  • Takahashi T; Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
PLoS One ; 16(3): e0249005, 2021.
Article em En | MEDLINE | ID: mdl-33770132
During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months-15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%-46%) and 74% (95% CI, 39%-89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%-77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estações do Ano / Vacinas contra Influenza / Testes Diagnósticos de Rotina / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Vírus da Influenza A Subtipo H3N2 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estações do Ano / Vacinas contra Influenza / Testes Diagnósticos de Rotina / Influenza Humana / Vírus da Influenza A Subtipo H1N1 / Vírus da Influenza A Subtipo H3N2 Idioma: En Ano de publicação: 2021 Tipo de documento: Article